Marcia Brose, MD, PhD, discusses a global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.
Marcia Brose, MD, PhD, director of the Center for Rare Cancers and Personalized Therapy, director of the Thyroid Cancer Therapeutics Program, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, and associate professor of Medicine at Penn Medicine, discusses a global, non-interventional study that assessed the use of sorafenib (Nexavar) as treatment of patients with asymptomatic radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
Brose explains that this study gave an idea of what the real-world responses are. The median duration of exposure to sorafenib was 15.6 months; the most common dose and frequency was a full dose of 400 mg twice daily. In the overall population of all 647 patients, the median overall survival (OS) was about 13.9 years from the time of original diagnosis. There was a median time to symptomatic progression from the initial visit of about 55 months and a 36-month time to symptomatic progression rate of 64%. The OS for the initial visit was not reached because patients were still responding at the time of the final analysis.
When looking at this study, the most important part is the real-world median, according to Brose. The real-world median for progression-free survival (PFS) with sorafenib was 16.7 months, and the 36-month PFS rate was 25.4 months.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More